Raoul Poupon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Raoul Poupon has a total of 193 co-authors. Here are the top co-authors by number of shared publications:
- M Biour
Centre Régional de Pharmacovigilance, Hôpital Saint-Antoine, Paris
11 shared publications O Chazouillères
11 shared publicationsG Cheymol
8 shared publicationsY Calmus
8 shared publicationsF Bodin
7 shared publications- Christophe Corpechot
Centre de Référence des Maladies Inflammatoires des VoiesBiliaires, Hôpital Saint-Antoine, APHP, Paris, France
6 shared publications
Latest Publications
- 1 September 2018
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 42 (4) , 294-295
Therapeutics Highlights from ILC 2018, the EASL annual congress
- 1 September 2018
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 42 (4) , 294-295
Therapeutics Highlights from ILC 2018, the EASL annual congress
- Open Access
- 1 March 2016
- Published by Elsevier in Journal of Hepatology
- Vol. 64 (3) , 537-538
ASBT inhibitors in cholangiopathies – Good for mice, good for men?
- 1 March 2016
- Published by Elsevier in Journal of Hepatology
- Vol. 64 (3) , 537-538
Open AccessASBT inhibitors in cholangiopathies – Good for mice, good for men?
- 1 February 2016
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 40 (1) , e1-e3
Fenofibrate-induced massive regression of mutiple inflammatory hepatocellular adenoma
- 1 February 2016
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 40 (1) , e1-e3
Fenofibrate-induced massive regression of mutiple inflammatory hepatocellular adenoma
- 1 April 2015
- Published by Elsevier in Journal of Hepatology
- Vol. 62, S796-S797
P1180 : Identification of pbc patients in need of additional therapy during the course of UDCA treatment -an international multicenter study
- 1 April 2015
- Published by Elsevier in Journal of Hepatology
- Vol. 62, S796-S797
P1180 : Identification of pbc patients in need of additional therapy during the course of UDCA treatment -an international multicenter study
- 1 April 2015
- Published by Elsevier in Journal of Hepatology
- Vol. 62, S795
P1177 : Risk factors for hepatic decompensation in primary biliary cirrhosis - results of an international follow up study of 2326 patients
- 1 April 2015
- Published by Elsevier in Journal of Hepatology
- Vol. 62, S795
P1177 : Risk factors for hepatic decompensation in primary biliary cirrhosis - results of an international follow up study of 2326 patients
- 24 February 2015
- Published by Wolters Kluwer Health in Hepatology
- Vol. 61 (6) , 2080-2090
Liver alkaline phosphatase: A missing link between choleresis and biliary inflammation
Several lines of evidence show that serum alkaline phosphatase (AP) is not only a signpost of cholestasis but also a surrogate marker of the severity of primary biliary cirrhosis and primary sclerosing cholangitis. In the present opinion article, we review and discuss the putative role of liver AP in health and in cholestatic diseases. In inflammatory cholestatic conditions, loss of activity of liver AP (resulting from its relocation from canaliculi and the acidic milieu) might promote hyper‐adenosine triphosphate‐bilia, lipopolysaccharide overload, and subsequent exacerbation and perpetuation of inflammation. Drugs that can restore the polarity of hepatocytes and canalicular export of bile acids or act as bile alkalinity modifiers are predicted to exert anti‐inflammatory effects and to benefit both primary biliary cirrhosis and primary sclerosing cholangitis. Oral administration of intestinal AP could be a valid therapeutic intervention that deserves further study under experimental conditions as well as in human diseases. Overall, the key role of the liver microenvironment that might shape the different facets of the inflammatory processes in fibrosing cholangiopathies is highlighted. (Hepatology2015;61:2080–2090)
- 24 February 2015
- Published by Wolters Kluwer Health in Hepatology
- Vol. 61 (6) , 2080-2090
Liver alkaline phosphatase: A missing link between choleresis and biliary inflammation
Several lines of evidence show that serum alkaline phosphatase (AP) is not only a signpost of cholestasis but also a surrogate marker of the severity of primary biliary cirrhosis and primary sclerosing cholangitis. In the present opinion article, we review and discuss the putative role of liver AP in health and in cholestatic diseases. In inflammatory cholestatic conditions, loss of activity of liver AP (resulting from its relocation from canaliculi and the acidic milieu) might promote hyper‐adenosine triphosphate‐bilia, lipopolysaccharide overload, and subsequent exacerbation and perpetuation of inflammation. Drugs that can restore the polarity of hepatocytes and canalicular export of bile acids or act as bile alkalinity modifiers are predicted to exert anti‐inflammatory effects and to benefit both primary biliary cirrhosis and primary sclerosing cholangitis. Oral administration of intestinal AP could be a valid therapeutic intervention that deserves further study under experimental conditions as well as in human diseases. Overall, the key role of the liver microenvironment that might shape the different facets of the inflammatory processes in fibrosing cholangiopathies is highlighted. (Hepatology2015;61:2080–2090)
- 1 October 2014
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 38 (5) , 550-556
Shaping macrophages function and innate immunity by bile acids: Mechanisms and implication in cholestatic liver diseases
- 1 October 2014
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 38 (5) , 550-556
Shaping macrophages function and innate immunity by bile acids: Mechanisms and implication in cholestatic liver diseases
- 1 April 2014
- Published by Elsevier in Journal of Hepatology
- Vol. 60 (1) , S34
O84 LIVER STIFFNESS ASSESSED BY FIBROSCAN IS A MAJOR PROGNOSTIC FACTOR IN PRIMARY SCLEROSING CHOLANGITIS
- 1 April 2014
- Published by Elsevier in Journal of Hepatology
- Vol. 60 (1) , S34
O84 LIVER STIFFNESS ASSESSED BY FIBROSCAN IS A MAJOR PROGNOSTIC FACTOR IN PRIMARY SCLEROSING CHOLANGITIS
- 1 April 2014
- Published by Elsevier in Journal of Hepatology
- Vol. 60 (1) , S55
O132 EFFECTIVE STRATIFICATION OF HEPATOCELLULAR CARCINOMA RISK IN PRIMARY BILIARY CIRRHOSIS: RESULTS OF A MULTI-CENTRE INTERNATIONAL STUDY
- 1 April 2014
- Published by Elsevier in Journal of Hepatology
- Vol. 60 (1) , S55
O132 EFFECTIVE STRATIFICATION OF HEPATOCELLULAR CARCINOMA RISK IN PRIMARY BILIARY CIRRHOSIS: RESULTS OF A MULTI-CENTRE INTERNATIONAL STUDY